The correlation of JAK2V617F with a proportion of chronic myeloproliferative disorders has generated numerous studies focused on the development of molecular-based assays for JAK2V617F detection. The current parallel study comparatively evaluated 3 JAK2V617F molecular detection methods. Genomic DNA from blood or bone marrow was assayed by 3 laboratories using allele-specific polymerase chain reaction (AS-PCR) or kit-based restriction fragment length polymorphism methods, which used polyacrylamide gel or capillary electrophoresis analysis. In addition, samples were sequenced in 2 of the laboratories. Results found 100% concordance among the 3 methods, with analytic sensitivities of 5% for both kit methods and 0.01% for AS-PCR. The kit-based assays detect JAK2V617F with equal sensitivity regardless of analysis method, and, despite greater sensitivity of AS-PCR, all 3 methods yielded 100% concordant results for this 36-sample set. Consistent with other reports, direct sequencing was insufficiently sensitive to serve as an initial diagnostic tool for JAK2V617F detection. © American Society for Clinical Pathology.
CITATION STYLE
Frantz, C., Sekora, D. M., Henley, D. C., Huang, C. K., Pan, Q., Quigley, N. B., … Mirza, I. (2007). Comparative evaluation of three JAK2V617F mutation detection methods. American Journal of Clinical Pathology, 128(5), 865–874. https://doi.org/10.1309/LW7Q3739RBRMBXXP
Mendeley helps you to discover research relevant for your work.